{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:58:57Z","timestamp":1764842337544,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.reuma.2019.11.001","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T17:12:45Z","timestamp":1581354765000},"page":"329-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efectividad del tocilizumab intravenoso en la pr\u00e1ctica cl\u00ednica usual de una cohorte de pacientes costarricenses con artritis reumatoide"],"prefix":"10.1016","volume":"17","author":[{"given":"Mauricio","family":"Cordero-Alfaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Le\u00f3n-C\u00e9spedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Ramos-Esquivel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2019.11.001_bib0135","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.reuma.2019.11.001_bib0255","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2019.11.001_bib0260","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"The therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor a monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2019.11.001_bib0265","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.reuma.2019.11.001_bib0270","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2019.11.001_bib0275","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2019.11.001_bib0280","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.reuma.2019.11.001_bib0170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2019.11.001_bib0175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","article-title":"Efficacy and safety of subcutaneous tocilizumab versus intravenous toci-lizumab in combination with traditional DMARDs in patients with RA at week97 (SUMMACTA)","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2019.11.001_bib0285","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2019.11.001_bib0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14397595.2016.1206507","article-title":"Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study","volume":"27","author":"Ishiguro","year":"2017","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.reuma.2019.11.001_bib0290","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2019.11.001_bib0295","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjmed.2013.09.002","article-title":"Racial and Ethnic Disparities in Disease Activity in Rheumatoid Arthritis Patients","volume":"126","author":"Greenberg","year":"2013","journal-title":"Am J Med."},{"key":"10.1016\/j.reuma.2019.11.001_bib0200","first-page":"1475","article-title":"Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study","volume":"34","author":"Bruce","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2019.11.001_bib0300","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40744-018-0130-6","article-title":"Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational","volume":"5","author":"Haraoui","year":"2018","journal-title":"Noninterventional Study. Rheumatol Ther."},{"key":"10.1016\/j.reuma.2019.11.001_bib0305","first-page":"21","article-title":"Analysis of Effectiveness. Safety and Optimization of Tocilizumab in a Cohort of Patients With Rheumatoid Arthritis in Clinical Practice","volume":"15","author":"Mena-V\u00e1squez","year":"2019","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2019.11.001_bib0310","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10067-017-3846-8","article-title":"Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics\u2019 register GISEA","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.reuma.2019.11.001_bib0315","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2019.11.001_bib0225","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/ecp.11.33","article-title":"Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis","volume":"4","author":"Zhang","year":"2011","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.reuma.2019.11.001_bib0320","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","article-title":"Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice","volume":"53","author":"Pers","year":"2014","journal-title":"Rheumatology."},{"key":"10.1016\/j.reuma.2019.11.001_bib0325","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.semarthrit.2015.07.001","article-title":"Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice","volume":"45","author":"Narv\u00e1ez","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reuma.2019.11.001_bib0330","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.semarthrit.2017.10.022","article-title":"The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab","volume":"47","author":"D\u00edaz-Torne","year":"2018","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reuma.2019.11.001_bib0335","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/acr.21680","article-title":"Early rheumatoid arthritis in Latin America: Low socioeconomic status related to high disease activity at baseline","volume":"64","author":"Massardo","year":"2012","journal-title":"Arthitis Care Res."},{"key":"10.1016\/j.reuma.2019.11.001_bib0250","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.120447","article-title":"Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results","volume":"40","author":"Fleischmann","year":"2013","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2019.11.001_bib0340","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/rheumatology\/kex238","article-title":"Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate","volume":"56","author":"Morel","year":"2017","journal-title":"Rheumathology (Oxford)."},{"key":"10.1016\/j.reuma.2019.11.001_bib0345","doi-asserted-by":"crossref","first-page":"e15947","DOI":"10.1097\/MD.0000000000015947","article-title":"Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab","volume":"98","author":"Corominas","year":"2019","journal-title":"ACT-AXIS study. Medicine (Baltimore)."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X19301639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X19301639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:00:57Z","timestamp":1761663657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X19301639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1699258X19301639"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2019.11.001","relation":{},"ISSN":["1699-258X"],"issn-type":[{"type":"print","value":"1699-258X"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectividad del tocilizumab intravenoso en la pr\u00e1ctica cl\u00ednica usual de una cohorte de pacientes costarricenses con artritis reumatoide","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}